Korean pharmaceutical and biotech sector is expanding exchanges with Basel of Switzerland, the center of Europe’s pharmaceutical and biotech industry. Basel is the base of European global big pharmas where 700 companies and 1,000 research institutions are located.

According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), the organization’s delegates participated in the special showcase hosted by the Basel Area Business and Innovation on October 27th, and had a time with local research institutions, universities and companies. Delegates were composed of the KBPMA’s global division, and the representatives from Yuhan and Hanmi Pharmaceutical to facilitate global open innovation.

This event was held in accordance with the Basel Launch KPBMA customized program domain partnership agreement signed by the KBPMA along with five participants including Yuhan, Hanmi Pharmaceutical, Ildong Pharmaceutical, Chong Kun Dang and Daewoong Pharmaceutical in January.

At the showcase hosted by the Basel Area Business and Innovation for the KBPMA and participating companies, over 100 experts from the Swiss pharmaceutical industry and Basel-based companies attended and showed high interest in Korean pharmaceutical companies.

Yuhan presented the case of successful development of the anticancer drug ‘Leclaza’ through open innovation and licensing deals with domestic and overseas pharmaceutical companies. It plans to expand partnerships with the European region to lay the groundwork for entry into Europe soon.

Hanmi Pharmaceutical presented its innovative R&D efforts from 2015 to recently, such as signing a large-scale licensing contract with a global big pharma.

Hanmi Pharmaceutical said, “Under the circumstances where we continue our efforts to develop global new drugs, the US Food and Drug Administration (FDA) has approved Rolontis, a neutrophil reduction treatment. We are actively seeking cooperation with Swiss, the center of European pharmaceutical industry.”

The KBPMA explained that the delegates had a time to listen to and discuss how Basel was able to rise as a global pharmaceutical and biotech center through active industry-university cooperation in the presence of Prof. Simon Grombacher Reynert of the Biozentrum at the University of Basel and Prof. Sebastian Wendeborn, Dean of University of Applied Sciences and Arts Northwestern Switzerland (FHNW).

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]

chop23@wikileaks-kr.org

Cho Pil Hyun, Staff Reporter 다른기사 보기

• facebook
• 트위터
• 카카오톡
• 네이버블로그
• 유튜브